WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Nycomed

NycomedNycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated total sales of €3.2 billion in 2009 and an adjusted EBITDA of €1.1 billion.

www.nycomed.com

Nycomed RSS Channel

Filters
List of articles in category Nycomed
Title Published Date
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 18 January 2012
Nycomed reports double-digit growth across emerging markets in second quarter 2011 17 August 2011
Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific markets 16 June 2011
Nycomed continues to outperform in emerging markets in first quarter 2011 26 May 2011
Nycomed acquires distribution rights to product portfolio in Turkey 14 April 2011
REACT study to evaluate impact of Daxas® (roflumilast) in patients receiving standard COPD treatment 31 March 2011
Nycomed well positioned in emerging markets 02 March 2011
Nycomed's novel COPD therapy roflumilast receives FDA approval 01 March 2011
Nycomed to acquire Colombian company Farmacol 06 February 2011
Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines 06 January 2011
Nycomed is keeping the pace in third quarter 2010 10 November 2010
Nycomed to accelerate expansion in China 01 November 2010
Global market launch of Daxas® (Roflumilast) kicks off in Germany 01 September 2010
Nycomed's Daxas® (roflumilast) receives marketing authorisation in the European Union 07 July 2010
Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® 03 May 2010
Nycomed and Baxter receive FDA approval for TachoSil® 08 April 2010
Nycomed on track in 2009 with strong growth in Key Products 02 March 2010
Nycomed reports continued satisfactory performance in the third quarter 2009 13 November 2009
Nycomed reports sustained momentum in second quarter 2009 20 August 2009
Nycomed and Forest Laboratories to collaborate on US commercialisation of Daxas® in COPD 11 August 2009
  • Start
  • Prev
  • 1
  • 2
  • Next
  • End

Business & Industry

  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
  • AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge

Research & Development

  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer
  • Engineered bacteria find tumors, then alert the authorities
  • First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Nycomed

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.